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Introduction {#sec1}
============

Lipid droplets (LDs) are dynamic organelles into which excess amounts of biochemical energy are deposited in the form of triacylglycerols (TAGs), together with cholesteryl esters (CEs) ([@bib55]). A single, large lipid droplet often occupies almost the entire cytoplasmic compartment in white adipose tissues (WATs) for TAG storage, whereas a series of tiny LDs exist in brown adipose tissues (BATs), from which TAGs are mobilized and fatty acids (FAs) are released when energy is needed. The accumulation of enlarged LDs in the liver may lead to obesity, hepatic steatosis, cardiovascular disease, and other metabolic diseases ([@bib15]). Obesity, known as a chronic progressive disease, as declared by the World Obesity Federation and other organizations ([@bib9]), is characterized by an abnormal or excessive accumulation of fat that negatively affects the optimal state of health ([@bib45]).

The triacylglycerols (TAGs) maintained in LDs are regulated by multiple enzymes, such as glycerol-3-phosphate-O-acyltransferase (GPAT), 1-acylglycerol-3-phosphate-O-acyltransferase (AGPAT), phosphatidic acid phosphatase (PAP, also known as lipin), and diacylglycerol acyltransferase (DGAT) ([@bib40]; [@bib50]). TAGs lipolysis is catalyzed step-by-step with patatin-like phospholipase domain-containing 2 (PNPLA, also known as ATGL), followed by the action of hormone-sensitive lipase (HSL) and monoacyl glycerol lipase (MGL) ([@bib35]; [@bib69]). Multiple proteins that are primarily located in the endoplasmic reticulum (ER) regulate TAG synthesis and the lipolysis of LDs and are transferred through membrane bridges between the ER and the LDs. It has been reported that the establishment of membrane bridges between the ER and LDs is triggered by coat protein complex I (COPI) ([@bib51]; [@bib62], [@bib61]) and mediates the transport of ATGL to the LD surface ([@bib5]; [@bib13]; [@bib28]; [@bib47]). The lack of ATGL results in a defect in lipolysis and leads to the accumulation of TAGs in adipose tissue (AT), heart, and muscle ([@bib17]; [@bib46]).

Oxysterol-binding protein (OSBP) and OSBP-related proteins (ORPs) constitute a large family of lipid transfer proteins (LTPs) that bind cholesterol, oxysterols, and anionic phospholipids through a conserved hydrophobic binding domain ([@bib2]; [@bib21]). Additional membrane-targeting motifs allow OSBP/ORPs to simultaneously associate with a diverse set of protein and lipid partners in organelle membranes, thus positioning the lipid-binding domain in close apposition to donor and acceptor membranes to facilitate transfer or signaling functions. OSBPL2, also known as ORP2, is a member of this large family of LTPs and contains an FFAT (diphenylalanine in an acidic tract) motif for ER targeting and a functional OSBP-related domain (ORD) for lipid binding and transfer ([@bib58]). OSBPL2 is reported to be involved in the metabolism of neutral lipids ([@bib18]; [@bib24]), but the molecular mechanism of how OSBPL2 regulates energy metabolism has not yet been fully elucidated.

Herein, we showed that LDs were enlarged in *OSBPL2*^*−/−*^ HepG2 cells with defective lipolysis. Furthermore, the AT in *Osbpl2b*^−/-^ zebrafish models presented with larger LDs and the resultant obesity phenotypes, which suggested that *OSBPL2* mutation altered the ER and LD connections that mediate lipid and protein trafficking. We showed that OSBPL2/ORP2 binds to COPB1 and participated in the transfer of proteins initially localized in the ER. Accordingly, OSBPL2 deficiency caused reduced transfer of ATGL from the ER to LDs, which led to a decrease in lipolysis and caused obesity. Overall, our study provided important insights into the function of OSBPL2, and the results strongly suggest that OSBPL2 could be a promising target for the treatment of obesity in humans.

Results {#sec2}
=======

*OSBPL2* Deficiency Is Associated with an Increase in LD Size and the Dynamic Changes in the ER and LDs {#sec2.1}
-------------------------------------------------------------------------------------------------------

LDs are cellular organelles that are the major sites of fat storage in tissues. Each LD is composed of hydrophobic neutral lipid cores containing triacylglycerols (TAGs) and cholesteryl esters, an encapsulating monolayer membrane of phospholipids and a series of surface proteins involved in lipid synthesis, lipolysis, and many other functions. The LD composition and size are different in diverse tissues ([@bib71]). TAGs are found in white adipose tissues (WAT) in the form of single giant LDs and several smaller droplets in the liver. The increased size of LDs provides an efficient form of fat storage, in terms of surface-to-volume ratio, to prevent lipotoxicity and hepatic steatosis ([@bib14]).

To study the biological function of OSBPL2 in lipid metabolism, we generated *OSBPL2*-deficient HepG2 cells by using the CRISPR-Cas9 gene-editing technique through which amino acid sequence is truncated and altered ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). The western blot analysis results showed that the OSBPL2/ORP2 band almost completely disappeared in *OSBPL2*^*−/−*^ cells compared with that of the wide-type (WT) cells ([Figure S1](#mmc1){ref-type="supplementary-material"}C).

To clarify the biological effect of *OSBPL2* deletion, we treated HepG2 cells with oleic acid (OA), a lipogenic stimulus ([@bib23]), for 16 h. Compared with those in the WT cells, more large LDs were formed in *OSBPL2*^*−/−*^ cells ([Figures 1](#fig1){ref-type="fig"}A and 1B). To obtain images of the LD in the WT cells and *OSBPL2*^*−/−*^ cells, confocal microscopy was used, and fluorescence staining of LDs was performed with BODIPY 493/503 to delineate LD sizes and distribution patterns ([Figure 1](#fig1){ref-type="fig"}A). Using this approach, we confirmed an increase in number of large LDs and a decrease in number of small LDs in the *OSBPL2*^*−/−*^ cells ([Figure 1](#fig1){ref-type="fig"}A). As described ([@bib42]), we also measured the LD size with ImageJ software and analyzed the LD distribution in the WT cells and *OSBPL2*^*−/−*^ cells. The population of LDs with a diameter of 3--4 μm increased, whereas the population of LDs with a diameter 1--2 μm decreased in the *OSBPL2*^*−/−*^ cells ([Figure 1](#fig1){ref-type="fig"}B). These results indicated that *OSBPL2* deficiency caused LD accumulation with an increase in large LDs and a decrease in small LDs. In addition, the TAG, CE, and TC were measured to find whether OSBPL2/ORP2 regulates TAG or CE synthesis. We found that the TAG level increased in *OSBPL2*^*−/−*^ cells compared with that in WT cells treated with OA for 16 h using a TAG biochemical detection kit ([Figure 1](#fig1){ref-type="fig"}C), but there were no significant differences in CE levels between WT cells and *OSBPL2*^−/−^ cells ([Figure 1](#fig1){ref-type="fig"}D). The above results indicated that *OSBPL2* deletion had little impact on the CE level but TAG in LDs. Consistent with previous data ([@bib57]; [@bib70]), we also found that *OSBPL2* deficiency increased the total cholesterol (TC) level ([Figure 1](#fig1){ref-type="fig"}E). The above indicates that *OSBPL2* deficiency may cause an increase of free cholesterol (FC) but not CE.Figure 1*OSBPL2*deficiency Enlarges Intracellular Lipid Droplets and Alters the Length of the ER--LD Contacts(A) Confocal imaging of the WT cells and *OSBPL2*^−/−^ cells using BODIPY 493/503 (green) and DAPI (blue) fluorescence staining. Scale bar, 10 μm (inserts, 2.5 μm).(B) Distribution of LDs in the HepG2 cells measured using ImageJ software.(C) The concentration of TAG in the WT cells and *OSBPL2*^−/−^ cells.(D) The concentration of CE in the WT cells and *OSBPL2*^−/−^ cells.(E) The concentration of TC in the WT cells and *OSBPL2*^−/−^ cells.(F and G) TEM images of LDs and the ER in the WT cells and *OSBPL2*^−/−^ cells. The scale bars in the original and magnified images represent 2 μm and 500 nm, respectively.(H) Total LD area per cell.(I) Total length of ER--LD contacts per cell.HepG2 cells were treated with or without 400 μM OA for 16 h (A). Data were collected from at least 2,000 LDs (B). The arrows indicated the ER--LD contacts; the lengths of ER--LD contacts were measured by ImageJ software within a 30 nm distance (F and G). Data were collected from 16 to 32 cells, with four images from each set analyzed (H and I). All the data represent the mean ± SD; t test significance (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001).

As is well known, LDs originate in the ER ([@bib6]; [@bib10]); when they become mature, LDs eventually separate from the ER through budding and enter into the cytoplasm ([@bib16]; [@bib20]; [@bib38]). Recent studies indicate that inter-organelle membrane contact sites (MCSs) are associated with lipid metabolic reactions ([@bib41]). Previous studies have also shown that OSBPL2/ORP2 is located on the surface of LDs and at ER--LD contact sites ([@bib18]; [@bib24]). To clarify the role of OSBPL2/ORP2 on the dynamic changes observed in ER and LDs, we used transmission electron microscopy to observe LDs and the ER in *OSBPL2*^*−/−*^ cells and WT cells grown with or without added OA loading ([Figures 1](#fig1){ref-type="fig"}F and 1G). Generally, the total LD area and the length of the ER-LD contacts were both increased when cells were supplemented with OA for 16 h. Consistent with previous fluorescence staining results ([Figures 1](#fig1){ref-type="fig"}A and 1B), we also found that the LD area in the *OSBPL2*^−/−^ cells was larger than that in the WT cells upon OA treatment ([Figure 1](#fig1){ref-type="fig"}H). However, the length of the ER-LD contacts was expanded in the WT cells, whereas no significant change was observed in the *OSBPL2*^*−/−*^ cells ([Figure 1](#fig1){ref-type="fig"}I), indicating that the absence of OSBPL2/ORP2 inhibited the dynamic changes in the ER-LD contact sites. Our findings are consistent with the results reported in Huh7 cells ([@bib24]). Increasing evidence suggests that the ER-LD contact sites and membrane extensions mediate the transport of neutral lipids that are synthesized in the ER and the proteins residing the ER that are needed for LD growth, lipogenesis, and lipolysis ([@bib22]; [@bib26]; [@bib54]; [@bib62]). Our results suggested that the altered ER-LD contacts in the *OSBPL2*^*−/−*^ cells affected lipolysis and thus caused LD accumulation.

OSBPL2/ORP2 Plays an Important Role in Lipolysis but Not in Lipogenesis {#sec2.2}
-----------------------------------------------------------------------

The amount of LDs is known to be determined by the balance between lipogenesis and lipolysis. LD diameters increase within hours during lipogenesis progress, whereas LDs shrink as core lipids are catabolized to liberate FAs during lipolysis ([@bib55]). Thus, we next examined whether OSBPL2/ORP2 plays a role in LD formation or the progression of LDs breakdown. We first evaluated dynamic LD formation over an 8-h-period of treatment with OA ([Figure 2](#fig2){ref-type="fig"}A). We found no apparent differences in the changes in LD size distribution in the *OSBPL2*^*−/−*^ cells, compared with the change in LD distribution in the WT cells ([Figure 2](#fig2){ref-type="fig"}B). Next, we analyzed the key enzymes of TAG synthesis by measuring the mRNA expression level, including that of glycerol-3-phosphate O-acyltransferase (GPAT), 1-acylglycerol-3-phosphate O-acyltransferase (AGPAT), phosphatidic acid phosphatase (PAP), and diacylglycerol acyltransferase (DGAT). The qRT-PCR results showed that there were also no significant differences in the mRNA expression levels of these lipogenesis-related genes ([Figure S2](#mmc1){ref-type="supplementary-material"}A and [Table S1](#mmc1){ref-type="supplementary-material"}).Figure 2*OSBPL2* Deficiency Impairs Efficient Lipolysis and Increases ROS Levels(A) Confocal imaging with BODIPY 493/503 (green); DAPI (blue) fluorescence staining of the WT cells and *OSBPL2*^−/−^ cells during lipogenesis. Scale bar, 10 μm.(B) The dynamic changes of LDs on lipogenesis in the HepG2 cells.(C) Confocal imaging with BODIPY 493/503 (green); DAPI (blue) fluorescence staining of the WT cells and *OSBPL2*^−/−^ cells during lipolysis. Scale bar, 10 μm.(D) The dynamic changes of LDs on lipolysis in the HepG2 cells.(E) Mitochondrial ROS levels in the WT and *OSBPL2*^−/−^ HepG2 cells.HepG2 cells were treated with OA at 400 μM for the indicated time points in (A) and (C). LDs were measured using ImageJ software. Data were collected from at least 2,000 LDs in each treatment, and the dynamic changes in LD size were analyzed by Gaussian distribution curves using GraphPad Prism software with data from (B) and (D). All the data represent the mean ± SD; t test significance (^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001).

Next, we focused on the progress of LD breakdown to determine whether *OSBPL2* deficiency impacted the effect of lipolysis. The cells were cultured in OA-containing medium for 24 h, followed by a chase of lipids for 48 h in fatty-acid-free medium (OPTI-MEM, 5% fatty-acid-free BSA) to induce TAG breakdown. The size of most LDs in the WT cells decreased over time, whereas only a small fraction of supersized LDs were changed in the *OSBPL2*^*−/−*^ cells ([Figure 2](#fig2){ref-type="fig"}C). The peak value of the curves representing the size of most of the LDs in fatty-acid-free medium was changed at the time of TAG breakdown ([@bib18]), suggesting that the mobilization of TAGs was slowed in the absence of *OSBPL2* ([Figure 2](#fig2){ref-type="fig"}D). To confirm the effect of OSBPL2/ORP2 on lipolysis, we measured the expression of lipolysis-related genes, such as carnitine palmitoyltransferase 1 (CPT1), carnitine palmitoyltransferase 2 (CPT2), acetyl-CoA carboxylase (ACC), PNPLA (also known as ATGL), hormone-sensitive lipase (HSL), and COPI coat complex subunit beta 1 (COPB1), with qRT-PCR. These genes play important roles in TAG mobilization, energy metabolism, and lipase trafficking to regulate lipolysis. As shown in [Figure S2](#mmc1){ref-type="supplementary-material"}B and [Table S1](#mmc1){ref-type="supplementary-material"}, *OSBPL2* deficiency led to the upregulated expression of *ACC*, *GPD2*, *CPT1,* and *CPT2*. In addition, considering that excessive TAGs might induce intracellular reactive oxygen species (ROS) production ([@bib11]; [@bib36]), we detected ROS levels by flow cytometry. As expected, the ROS levels of *OSBPL2*^*−/−*^ cells were ∼80% higher than those of WT cells under basic condition and ∼50% higher than those of WT cells treated with OA ([Figure 2](#fig2){ref-type="fig"}E).

Taken together, these data suggest that intracellular *OSBPL2* deletion impacts the progress of lipolysis rather than LD formation or morphological changes in LDs.

OSBPL2/ORP2 Is Required for the Transport of ATGL from the ER to LDs {#sec2.3}
--------------------------------------------------------------------

To address how lipolysis is regulated by OSBPL2/ORP2, we focused on the rate-limiting lipases of lipolysis more closely. In the lipolysis process, the LD volume decreased as core lipids were catabolized sequentially by ATGL, HSL, and monoacylglycerol lipase ([@bib55]). Of the three lipases, ATGL is the key lipase for the first rate-limiting step ([@bib55]; [@bib68]). Consistent with previous reports ([@bib49]), our findings verified that ATGL attached to the LDs in the HepG2 cells treated with OA ([Figure 3](#fig3){ref-type="fig"}A). It was observed that there were no significant differences in *ATGL* expression levels between the WT cells and *OSBPL2*^−/−^ cells ([Figure S2](#mmc1){ref-type="supplementary-material"}B), so we measured ATGL to assess whether similar results would be obtained at protein expression level. We found no significant differences in the protein expression level of ATGL in *OSBPL2*^*−/−*^ cells compared with the level in the WT cells ([Figure S2](#mmc1){ref-type="supplementary-material"}C).Figure 3*OSBPL2* Deficiency Leads to a Handicap of ATGL Transport from the ER to LDs.(A) Confocal imaging of the WT or *OSBPL2*^−/−^ HepG2 cells using BODIPY 493/503 (green), DAPI (blue), and anti-ATGL (red) immunostaining. Scale bar, 5 μm (inserts, 2.5 μm).(B) A reconstructed 3D image of the WT and *OSBPL2*^−/−^ HepG2 cells treated with OA using BODIPY 493/503 (green), DAPI (blue), and anti-ATGL (red) immunostaining. Scale bar, 10 μm.(C) Percentage of cells that showed the localization of endogenous ATGL on LDs.(D) Confocal images showing the localizations of RFP-OSBPL2 in the WT cells treated with or without BFA using BODIPY 493/503 (green) and DAPI (blue). Scale bar, 5 μm (inserts, 2.5 μm).(E) Percentage of cells expressing RFP-tagged OSBPL2 that showed LD localization.HepG2 cells were treated with 400 μM OA for 16 h (A and B). The main portion is indicated in the xy image. The two rectangular panels (top and right) are xz and yz images, respectively (B). HepG2 cells were transfected with RFP-tagged OSBPL2 for 24 h, then treated with 400 μM OA and 10 ng/mL BFA (D). All the data represent the mean ± SD; t test significance (^∗∗∗^p \< 0.001).

We next focused on the location of endogenous ATGL to determine whether *OSBPL2* deletion altered the distribution of ATGL on the LDs. Previous studies in *Drosophila* S2 cells and HeLa cells demonstrated that ATGL is transferred from the ER membrane to LD surface by the COPI machinery ([@bib47]; [@bib61]). Using z stack of confocal scanning after cells received OA supplement, we observed an abundant of ATGL wrapped around LDs in WT cells, whereas few ATGL proteins were visibly attached to the LDs in the *OSBPL2*^*−/−*^ cells. This result in the *OSBPL2*^*−/−*^ cells was similar to that in the WT cells treated with brefeldin A (BFA, an inhibitor of COPI machinery), which caused a disruption of ATGL trafficking to LDs ([Figures 3](#fig3){ref-type="fig"}A--3C). We blocked the COPI machinery with BFA to verify the attachment of OSBPL2/ORP2 to the LDs. Using the method as described ([@bib12]), the WT cells were transfected with RFP-tagged OSBPL2/ORP2 and the localization of OSBPL2/ORP2 to the LDs was quantified. The results indicated that the degree of co-localization of OSBPL2/ORP2 with LDs was unaffected, suggesting that the localization of OSBPL2/ORP2 on the LDs is independent of the COPI machinery ([Figures 3](#fig3){ref-type="fig"}D and 3E).

Based on earlier discussion, we confirmed that the expression of ATGL was not altered both at the mRNA and protein levels, and we also found an abnormal localization of ATGL on the LDs in the *OSBPL2*^*−/−*^ cells, suggesting that *OSBPL2* deficiency interfered with the distribution of ATGL, but not its abundance, on the LDs. The results implied that OSBPL2/ORP2 is required in the transport of ATGL and is possibly an underlying protein involved in the COPI machinery that mediates ATGL during lipolysis.

OSBPL2/ORP2 Binds to COPB1 and Downregulates COPB1 Expression Levels {#sec2.4}
--------------------------------------------------------------------

Given that *OSBPL2* deficiency hindered ATGL transport, we sought to determine its intrinsic regulatory mechanisms. We had previously identified 47 proteins by proteomic analysis of the OSBPL2/ORP2 interactome and found COPA and COPB1, both COPI coat complex subunits, among the binding partners of OSBPL2/ORP2. FLAG-tagged OSBPL2/ORP2 was previously constructed and expressed in HEK293Ta cells, and then, the protein complex was pulled down with anti-FLAG magnetic beads and analyzed by mass spectrometry. The proteomic analysis revealed an interaction between OSBPL2/ORP2 and candidate proteins, which prompted us to confirm that the two proteins are associated with each other at the molecular level. Co-immunoprecipitation (Co-IP) experiments showed a specific interaction of FLAG-tagged OSBPL2/ORP2 with transfected COPA in HEK293Ta cells ([Figure 4](#fig4){ref-type="fig"}A), and we also found a specific interaction of FLAG-tagged OSBPL2/ORP2 with transfected COPB1 in HEK293Ta cells ([Figure 4](#fig4){ref-type="fig"}B). Because COPB1, but not COPA, is associated with lipid droplet accumulation ([@bib25]; [@bib61]), another laboratory suggested that COPB1 might play an important role in confining COPI orientation relative to the membrane ([@bib67]), and our qPCR results also indicated that knocking out *OSBPL2* caused changes in COPB1. Similarly, the physical interaction of endogenous OSBPL2/ORP2 with endogenous COPB1 was validated in HepG2 cells ([Figure 4](#fig4){ref-type="fig"}C). More interestingly, we found that *OSBPL2* deficiency led to an increase in COPB1 expression, *OSBPL2* overexpression significantly decreased the expression level of COPB1, and *OSBPL2* transfection in *OSBPL2*^*−/−*^ cells also reduced COPB1 expression ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). Moreover, a similar trend was observed among OA-treated cells ([Figures S3](#mmc1){ref-type="supplementary-material"}D--S3G).Figure 4OSBPL2 Binds to COPB1, and *OSBPL2* Deficiency Leads to Hindered COPB1 Localization to the LDs(A) Co-IP assay verified the interaction of FLAG-tagged OSBPL2 with HA-tagged COPA in the HEK293Ta cells.(B) Co-IP assay verified the interaction of FLAG-tagged OSBPL2 with HA-tagged COPB1 in the HEK293Ta cells.(C) Co-IP assay verified the interaction of endogenous OSBPL2 with endogenous COPB1 in HepG2 cells.(D) Western blot of whole-cell lysate (WCL), post nuclear supernatant (PNS), and LD proteins in the WT and *OSBPL2*^−/−^ cells.(E) Co-IP assays verified the interaction of FLAG-tagged OSBPL2 with HA-tagged ATGL in the HEK293Ta cells.(F) Confocal imaging of the WT cells or *OSBPL2*^−/−^ cells using BODIPY 493/503 (green), DAPI (blue), and anti-COPB1 (red) immunostaining. Scale bar, 5 μm (inserts, 2.5 μm).(G) A reconstructed 3D image of the WT cells and *OSBPL2*^−/−^ cells treated with OA using BODIPY 493/503 (green), DAPI (blue), and anti-COPB1 (red) immunostaining. Scale bar, 10 μm.(H) Percentage of cells that show the localization of endogenous COPB1 on LDs.HepG2 cells were treated with 400 μM OA for 16 h and treated with or without 10 ng/mL BFA (F). The main portion is shown in the xy image. The two rectangular panels (top and right) are the xz and yz images, respectively (G). All the data represent the mean ± SD; t test significance (^∗^p \< 0.05, ^∗∗^p \< 0.01).

Although we have demonstrated that OSBPL2/ORP2 binds to COPB1 and that *OSBPL2* deletion upregulates COPB1 expression levels, how OSBPL2/ORP2 regulates the expression of COPB1 and how OSBPL2/ORP2 regulates ATGL transport remain unknown. We suggest that an underlying molecular mechanism combines OSBPL2/ORP2 with COPB1 and ATGL to facilitate ATGL localization on LDs.

OSBPL2/ORP2 Is Required for COPB1 Localization to LD Surfaces and ATGL Transport from the ER and Attachment to LDs {#sec2.5}
------------------------------------------------------------------------------------------------------------------

It has been reported that the transport of GPAT4, which originates in the ER, to LDs requires COPB1 ([@bib61]). Similar to GPAT4, ATGL transport from the ER to LDs also depends on the COPI machinery; therefore, we compared the localization of COPB1 in the *OSBPL2*^*−/−*^ cells with that in the WT cells. The cells were treated with OA for 16 h, and the lysate was then divided into whole-cell lysate (WCL), post nuclear (PNS), and LD fractions as described ([@bib30]). Similar to the finding with ATGL, fewer COPB1 molecules were targeted to LDs in the *OSBPL2*^*−/−*^ cells, as determined by western blotting ([Figure 4](#fig4){ref-type="fig"}D). In addition, Co-IP was performed, and the results showed that HA-tagged ATGL was detected in the FLAG-tagged OSBPL2/ORP2 complexes but was absent in the negative control ([Figure 4](#fig4){ref-type="fig"}E), supporting the supposition that ATGL specifically interacts with OSBPL2/ORP2. As shown by fluorescence microscopy, we found that COPB1 wrapped around the LDs in the WT cells but not in the WT cells treated with BFA or in the *OSBPL2*^*−/−*^ cells ([Figures 4](#fig4){ref-type="fig"}F--4H) supplemented with OA, implying that OSBPL2/ORP2 is required for COPB1 localization on the LDs. The data suggested that OSBPL2/ORP2 binds to COPB1 and that the complex is involved in ATGL transport. Finally, we knocked down COPB1 using siRNA to confirm that the disrupted expression of COPB1 leads to blocked ATGL transport. As expected, confocal scanning imaging showed that the extent of ATGL localization to the LDs was reduced when COPB1 was knocked down ([Figures S3](#mmc1){ref-type="supplementary-material"}H--S3J).

Together, the results showed that OSBPL2/ORP2 located to the LDs independent of COPI machinery, but it was bound to both COPB1 and COPA, which are the subunits of COPI that mediate ATGL trafficking for lipolysis. *OSBPL2* deletion reduced the location of COPB1 on the LDs and caused a hindrance to ATGL transport that was similar to that observed after COPB1 knockdown by siRNA. Furthermore, ATGL was suggested to interact with OSBPL2/ORP2. Thus, we conclude that OSBPL2/ORP2 is located on LDs and binds COPB1, which is in a complex that possibly transfers ATGL from the ER to LDs for lipolysis.

Aggravated Obesity Phenotypes and Abnormal Behavior in *Osbpl2b*-Deficient Zebrafish {#sec2.6}
------------------------------------------------------------------------------------

The results from our previous study showed that *OSBPL2*^*−/−*^ Bama mini pigs exhibited obvious obesity and hypercholesterolemia phenotypes ([@bib66]), and the established adult *osbpl2b*^*−/−*^ zebrafish have also shown abnormal lipid-metabolism-related characteristics. The *osbpl2b*^*−/−*^ zebrafish in this study were used to test whether altered osbpl2b disturbs energy homeostasis *in vivo*. There are two genes (*osbpl2a* and *osbpl2b*) in zebrafish that are homologous with human *OSBPL2*, and *osbpl2b* was proven to be the orthologous gene of human *OSBPL2* (OMIM: [606731](606731){#intref0010}) in our previous study, sharing identity of 71.2% with human OSBPL2 amino acid sequences ([@bib30]). The *osbpl2b*^*−/−*^ zebrafish were previously generated using the CRISPR/Cas9 gene-editing technique, through which a 5-nucleotide (GAGCT) deletion was generated in exon 6 and resulted in a truncated protein. This mutation in *osbpl2b* caused hearing impairment and lipid-metabolism-related characteristics (results are not shown). Adult WT zebrafish and *osbpl2b*^*−/−*^ zebrafish were allocated to groups and fed with the same basic chow (BC), for the WT-BC group and MT-BC group, or the same high-fat diet (HFD), for the WT-HFD group and MT-HFD group. Deletion of *osbpl2b* seemed to increase somatic growth and body weight, which were measured every month ([Figures 5](#fig5){ref-type="fig"}A and 5B). As described ([@bib34]), we next stained zebrafish with BODIPY 493/503, anesthetized the fish, and observed the fat distribution in the fish bodies using a fluorescence stereo microscope. Although there were no significant differences in the total adipose tissue (AT) area among the four groups as shown [Figure 5](#fig5){ref-type="fig"}C, we found that the livers of the MT group were larger and contained more fat attached on the surface, as observed when the fish were dissected ([Figure 5](#fig5){ref-type="fig"}D). Next, to determine the TAGs content accurately, we divided the adipocytes of the zebrafish body into three regions: miscellaneous AT (misc. AT), subcutaneous adipose tissue (SAT), and visceral adipose tissue (VAT). We then measured the LD size in adipocytes of different regions to determine whether the *osbpl2b* mutation altered fat distribution in zebrafish. Fluorescence staining with BODIPY 493/503 showed that the HFD treatment did not cause significant differences in miscellaneous AT in the WT-HFD group and MT-HFD group but caused a substantial increase in the LD area in the miscellaneous AT in the MT-BC group compared with that in the WT-BC group ([Figures 5](#fig5){ref-type="fig"}E and 5F). Furthermore, we found that SAT was increased in the MT group compared with the SAT level in the WT group fed either a BC or HFD ([Figures 5](#fig5){ref-type="fig"}E and 5G). Similar to SAT, VAT increased in the MT-HFD group; however, VAT in the MT-BC group did not expand obviously ([Figures 5](#fig5){ref-type="fig"}E and 5H). More interestingly, we observed abnormal behavior in the *osbpl2b*^*−/−*^ zebrafish, especially the MT-HFD group, which tended to live near the top of the water, whereas most of the WT zebrafish fed a BC or HFD lived in the middle of the fish tank ([Figures S4](#mmc1){ref-type="supplementary-material"}A, S4B, and [Video S1](#mmc2){ref-type="supplementary-material"}); this observation led us to consider possible lipid toxicity in the liver ([@bib8]; [@bib59]). Further data showed that *osbpl2b* deficiency led to an increase in food intake ([Figure S4](#mmc1){ref-type="supplementary-material"}C).Figure 5*osbpl2b* Deficiency Alters Somatic Growth and Exacerbates Fat Accumulation in Adult Zebrafish(A) Body weight curves.(B) Mean length of the fish bodies. The data represent the mean ± SD; t test significance (^∗^p \< 0.05).(C) Fluorescence imaging of total AT using BODIPY 493/503 staining. Scale bar: 2,000 μm.(D) A representative view images of the liver.(E) Fluorescence imaging of Misc. AT, VAT, and SAT using BODIPY 493/503 staining. Scale bar, 50 μm.(F--H) Distribution of LDs in Misc. AT, SAT, and VAT measured using ImageJ software.

Video S1. Relative position of zebrafishes in water tanks. Related to Figure 5.The WT-HFD group (left) and MT-HFD group (right) were maintained in buffered reverse osmosis water.

The results suggest that *osbpl2b* mutation could cause lipotoxicity in the liver and an obesity-like phenotype.

Reduced ER--LD Contact Area Lengths and Decreased Localization of COPB1 on LDs in the *osbpl2b*-Deficient Zebrafish {#sec2.7}
-------------------------------------------------------------------------------------------------------------------

The results of our *in vitro* experiments suggested that OSBPL2/ORP2 is located on LDs and COPB1 is bound in a complex that possibly transfers ATGL from the ER to LDs. We next focused on whether this molecular mechanism could mediate lipolysis in zebrafish. Fluorescence staining of fat distribution showed an increase in VAT and SAT in the *osbpl2b*^*−/−*^ zebrafish, and using Masson dye staining, we verified the morphological changes induced by *osbpl2b* deletion. Similar to the results shown in [Figures 5](#fig5){ref-type="fig"}E--5H, we found that SAT was increased in the *osbpl2b*^−/-^ zebrafish ([Figures 6](#fig6){ref-type="fig"}A--6C). H&E staining of liver tissue revealed exacerbated fat accumulation and edema with inflammation in the MT-HFD group ([Figure 6](#fig6){ref-type="fig"}D). As we suggested that *OSBPL2* depletion hinders the ATGL localization to the LD surface, we sought to determine whether a similar effect could be observed in the *osbpl2b*^*−/−*^ zebrafish. We observed LDs and the ER by transmission electron microscopy to evaluate the role of osbpl2b in the dynamic changes in the ER and LD contact in zebrafish. Similar to the results found *in vitro* ([Figures 1](#fig1){ref-type="fig"}F--1I), the length of the ER--LD contacts in liver tissue increased only for the WT-HFD group and did not change significantly in the MT-HFD group ([Figures 6](#fig6){ref-type="fig"}E and 6F). Furthermore, by detecting the extracted LD-associated proteins in the liver by western blotting, we detected a decrease in Copb1 targeted to the LDs in the MT-HFD group compared with that in the WT-HFD group ([Figures 6](#fig6){ref-type="fig"}G and 6H), suggesting that the mutation of *osbpl2b* in zebrafish led to a decrease of Copb1 on the LDs.Figure 6*osbpl2b* Deficiency Leads to Steatohepatitis and Reduces the Length of the ER--LD Contacts in the Liver(A) Masson\'s trichrome-stain zebrafish indicated the anatomical localization of SAT and liver. Muscle (m), swim bladder (sb), VAT, SAT, and liver are indicated with arrows. Scale bar: 1,000 μm.(B) Image of SAT using Masson\'s trichrome staining. Scale bar, 50 μm.(C) Distribution of LDs in SAT measured using ImageJ software.(D) H&E-stained histological sections indicating the morphology of the liver. Scale bar, 50 μm.(E) TEM imaging of the LDs and the ER in the livers. The scale bars in the original and magnified images represent 2 μm and 500 nm, respectively.(F) Total length of ER--LD contacts per cell.(G) Western blot of LD proteins in the WT-HFD and MT-HFD zebrafish.(H) Copb1 abundance in the LD fraction, which represented the quantification of images shown in G.The arrows indicated the ER--LD contacts, the lengths of ER--LD contacts were measured by ImageJ software within a 30 nm distance (E). Data were collected from 16 to 32 cells, with four images from each set analyzed (F). All the data represent the mean ± SD; t test significance (^∗^p \< 0.05).

These data obtained from zebrafish experiments are similar to the *in vitro* results and suggest a possible molecular mechanism: OSBPL2/ORP2 binds COPB1 in a complex that transfers ATGL from the ER to LDs for lipolysis, which explains why *OSBPL2* deficiency causes fat accumulation and energy metabolic disorder.

Discussion {#sec3}
==========

Our laboratory and others had previously identified that *OSBPL2* was associated with autosomal dominant nonsyndromic hearing loss ([@bib52]; [@bib63]; [@bib64]). To confirm the consistent effect of OSBPL2/ORP2 in hearing loss by both genotype and phenotype, we successfully simulated human hearing loss phenotypes in both Bama mini pig and zebrafish models. Especially in the *OSBPL2*-disrupted pigs, we reproduced not only a deafness phenotype similar to that of humans but also a hypercholesterolemia phenotype ([@bib66]). In subsequent studies of OSBPL2/ORP2 functions, we found that *OSBPL2* was downregulated by 25-hydroxycholesterol ([@bib60]). In OC1 cells, the deletion of *OSBPL2* led to increased cholesterol biosynthesis and upregulated ROS production ([@bib57]). In HeLa cells, *OSBPL2* deficiency was also proven to upregulate intracellular cholesterol and cholesteryl ester ([@bib70]). Recently, it was suggested that the deletion of *OSBPL2* in HuH7 cells reduce glucose absorption and glycogen synthesis and inhibited glycolysis ([@bib24]). In addition, others ([@bib18]; [@bib39]) have suggested that OSBPL2/ORP2 impacts cellular TAG and carbohydrate metabolism. These results indicate that OSBPL2/ORP2 has versatile functionality.

Our results have shown that OSBPL2/ORP2 is involved in the establishment of the ER-LD membrane contacts. One type of membrane contact sites (MCS) called an ER--LD contacts links adjacent membranes of the ER and apposed LDs without allowing them to fuse to each other. It has been reported that multiple proteins associated with ER--LD contacts are also involved in LD formation ([@bib19]). Rab18 and NAG-RINT1-ZW10 (NRZ) located at ER--LD points of a contact are involved in LD biogenesis in adipocytes ([@bib65]). With results similar to those from a previous study ([@bib24]), we found that *OSBPL2* deficiency impacts the dynamic change in the ER and LDs upon fatty acid addition. However, in contrast with the results obtained from cells treated with OA for 3 h, we further investigated whether the total LD area per cell was increased in the *OSBPL2*^*−/−*^ cells when cells were treated with OA for 16 h. The inconsistent results may be due to different treatment times and the effect of lipolysis. Our observation was consistent with a report ([@bib18]) showing that knocking down *OSBPL2* impacts lipolysis. The production of ROS is associated with energy metabolism. The activation or inhibition of the enzymes implicated in ROS production can affect cell structure and function ([@bib43]). Some hormonal and metabolic adaptations upregulate mitochondrial fatty acid oxidation (mtFAO) to restrain hepatic fat accumulation; however, they may also result in ROS overproduction rather than a reduction in fat accumulation in the liver ([@bib4]). Furthermore, deficiency in the coactivator of ATGL, comparative gene identification-58 (CGI-58) inhibits the lipolysis effect of ATGL and activates the ROS-inflammasome pathway ([@bib33]). Thus, the enhanced ROS level with LD enlargement appearing from our data can be viewed from another perspective to suggest that *OSBPL2* deletion possibly causes abnormal energy metabolism and leads to obesity.

Our data have identified that OSBPL2/ORP2 binds COPB1 in a complex that mediates protein transport. The vesicle coat proteins, such as coat protein I (COPI) and coat protein II (COPII), play an important role in regulating vesicle formation and mediate specific transport routes. COPI vesicles are considered to be mediators of transport back from the Golgi apparatus to the ER, whereas COPII vesicles transport cargo from the ER to the Golgi apparatus. The formation of the COPI complex associated with the ER and LDs requires the localized activation of a small GTPase at the LDs membrane. Guanine-nucleotide exchange factors catalyze and activate small GTPase through the exchange of GDP for GTP ([@bib7]). The clathrin-coated vesicles (CCVs) containing AP-2 (an adaptor protein complex) are recruited to the plasma membrane (PM) by phosphatidylinositol 4,5-bisphosphate \[PI(4,5)P2\] and cargo proteins ([@bib44]). We found that COPB1, a subunit of the COPI complex, is predicted to contain the AP-2 domain, as indicated by the CD-search online software, suggesting that COPB1 is possibly recruited to the PM by PI(4,5)P2, and a recent study has proven that OSBPL2 delivers cholesterol to the PM in exchange for PI(4,5)P2 ([@bib58]). Oxysterol-binding protein (OSBP) is reported to have the ability to both tether organelles and transport lipids between them, with an FFAT motif that interacts with the ER protein VAP-A and transfer sterol through the lipid transfer domain (ORD) ([@bib32]). Here, our evidence supports the position that OSBPL2/ORP2 binds to COPB1 and that OSBPL2/ORP2 localization to LDs is independent of COPI machinery. These findings suggested that OSBPL2/ORP2 linked the ER to the limiting membrane of LDs, which was followed by the recruitment of COPB1.

We have also identified OSBPL2/ORP2 as a lipid transfer protein involved in the transport of ATGL and lipolysis. Given that proteins targeting LDs have been classified into two paths ([@bib26]), class I proteins access LDs through ER-LD contact sites, and class II proteins bind to LDs directly from the cytosol. ATGL is one of the class I proteins considered to be the first embedded in the ER membrane through its hydrophobic hairpin motif, followed by its transfer to LDs. Previous studies have demonstrated that COPI mediates the membrane-trafficking pathway that contributes to the localization of ATGL to LDs via ER-LD membrane bridges ([@bib13]; [@bib47]). A recent study has proven that Arf1/COPI machinery controls ER-LD connections to mediate TAG storage and catabolism ([@bib61]). Similar to those from previous studies, our data demonstrate that *OSBPL2* deletion reduces the amount of COPB1 located on LDs and inhibits the establishment of the ER and LD membrane bridge, which in turn results in hindered ATGL transfer for TAG catabolism. In previous reports, nonbilayer lipids, such as cholesterol, can increase membrane tension, which was adverse to the egress of neutral lipids from the bilayer and LD budding ([@bib15]). In our study, the absence of OSBPL2/ORP2 causing cholesterol upregulation can be viewed from another perspective to support the effect on lipolysis.

As the regional distribution and morphology of AT are known to be predictors of metabolic disease ([@bib1]; [@bib3]), our observations *in vivo* show exacerbated fat accumulation and edema with inflammation in the *osbpl2b*-deficient liver and an increase in SAT and an expansion of VAT. Generally, high-fat diet-induced fat accumulation increases VAT and is followed by fat redistribution into subcutaneous tissue and other organs. Here, the expansion of VAT suggests that *osbpl2b* deficiency aggravates the fat accumulation induced by a high-fat diet. SAT expansion was reported to predict impaired glucose metabolism, hyperinsulinemia, and insulin resistance ([@bib27]; [@bib31]; [@bib48]), and other studies have suggested that increased SAT may store potentially toxic lipids in obese individuals ([@bib53]). Given that zebrafish are known to be predictors by changes in behavior or ventilatory patterns due to their sensitivity to toxic substances ([@bib37]; [@bib56]), the abnormal behavior associated with *osbpl2b* deficiency that drove some zebrafish to live in the top portion of the water tank was possibly due to an increase in oxygen consumption and lipid toxicity in the liver. We had previously reported that *osbpl2b* is highly expressed in the central nervous system (CNS) of zebrafish. The markedly increased feeding and the altered swimming behavior of the *osbpl2b*^−/-^ zebrafish most likely reflected functional impacts of the mutation on the CNS, the regions controlling appetite and satiety, and possibly the swimming behavior.

It has been reported that knocking down mysterin, which specifically eliminates ATGL from LDs, leads to a decrease in LDs in HeLa cells and a decrease in LDs in the head region of zebrafish ([@bib49]). In our study, we found that LDs are enlarged in *OSBPL2*^*−/−*^ cells, whereas VAT and SAT increase in the osbpl2b^−/-^ zebrafish. We have also found that COPB1 attachment to LDs is reduced both in the *OSBPL2*^*−/−*^ cells and in the *osbpl2b*^*−/−*^ zebrafish to reduce ATGL localization to the LDs. The observation made via TEM in a previous study indicated that DFCP1 regulates the size of LDs and the formation of ER-LD contacts ([@bib29]). In our study, we demonstrated that ER-LD contacts are altered when *OSBPL2*^*−/−*^ cells are treated with OA or when *osbpl2b*^*−/−*^ zebrafish are fed a high-fat diet. Consistent with this *in vitro* data, we obtained a series of similar results *in vivo*, suggesting that *OSBPL2* deficiency leads to an enhanced LD phenotype and impairment to ATGL localization on LDs at the molecular level.

Overall, this work presents the underlying molecular mechanism by which (1) OSBPL2/ORP2 binds to COPB1 in complex and maintains COPB1 located on LDs; (2) the OSBPL2-COPB1 complex mediates ATGL transfer from the ER to LDs; (3) ATGL wraps around the LDs during lipolysis; and (4) loss of OSBPL2/ORP2 enlarges LDs and changes lipid metabolism. Although this work has considerably improved our understanding of the function of OSBPL2/ORP2, OSBPL2/ORP2 regulates lipolysis and fat accumulation in human and may be the basis of therapeutic approaches that target *OSBPL2* biology in the treatment of metabolic disease.

Limitations of the Study {#sec3.1}
------------------------

Although OSBPL2/ORP2 has been proven to have multiple functions, including cholesterol transport, energy metabolism, and auditory function, the underlying molecular mechanism of OSBPL2/ORP2 is not fully understood. We acknowledge that the present study has several limitations, including the determination of the structure of the OSBPL2-COPB1 complex linking the ER and LDs. In addition, the abnormal zebrafish behaviors, such that the osbpl2b mutation causes an increase in food intake, are not understood. Future studies will focus on developing tools to determine the structure of the complex and to clarify the underlying reason for the altered zebrafish behavior.
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